A Phase 1 interventional study of AZD5004(Part A) and Placebo(Part A) in Healthy Participants and Type 2 Diabetes, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-21.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.
Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 5 that started in 2024, is one of 11 in phase 1, and was the 6th registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China, Hong Kong, Malaysia and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
AstraZeneca · Sites in United States, Bulgaria, China and 13 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 57 across the 18 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 217th largest by enrollment of the 280 interventional ones that give a count, is one of 4 that started in 2024, is one of 86 in phase 1, and was the 324th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing elecoglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07534592AstraZenecaA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | 2027-01-25 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This Phase I study will gather important information on the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5004 in both healthy Japanese participants and Japanese participants with T2DM.
This is a placebo-controlled study to assess the safety, efficacy, tolerability, and PK of single and repeated dosing of AZD5004 compared with placebo.
Participants who are eligible according to the inclusion/exclusion criteria will be randomized to receive AZD5004 or matching placebo.
The study will comprise:
Inclusion Criteria:
Inclusion Criteria for Part A:
Inclusion Criteria for Part B:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive AZD5004 orally.
Drug: AZD5004(Part A)
Participants will receive matching Placebo orally.
Drug: Placebo(Part A)
Participants will receive AZD5004 orally.
Drug: AZD5004(Part B)
Participants will receive matching Placebo orally.
Drug: Placebo(Part B)
Single dose of AZD5004 oral on Day1
Single dose of placebo oral on Day1
AZD5004 will be administered as an oral tablet once daily.
Placebo will be administered as an oral tablet once daily.
PartA: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
To assess the safety and tolerability of AZD5004 following single oral doses in healthy participants.
Time frame: From screening (Day -28) to last follow up visit (Day 8)
PartB: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
To assess the safety and tolerability of AZD5004 following multiple oral ascending doses in participants with T2DM.
Time frame: From screening (Day -28) to last follow up visit (Day 119 )
PartB: AUC0-4 for glucose, insulin and C-peptide for MMTT
To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: From Day 1 to Day 105
PartB: Absolute change from baseline to Day 105 in fasting plasma glucose
To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: From Day 1 to Day 105
PartB: % change from baseline to Day 105 in HOMA-IR
To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: From Day 1 to Day 105
PartB: The proportion of time in hyperglycaemia /hypoglycaemia over the last 7-day intervals at each dose level in CGM
To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: From Day 1 to Day 106
PartB: % change from baseline to Day 105 in body weight (kg)
To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: From Day 1 to Day 105
PartB: % change from baseline to Day 105 in waist circumference (cm)
To describe the PD of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: From Day 1 to Day 105
PartA: Area under the Plasma Concentration vs. Time Curve(AUC0-24)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Area under the Plasma Concentration vs. Time Curve from Zero until the Time of the Last Concentration above the Limit of Quantification(AUC0-tlast)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Area under the Plasma Concentration vs. Time Curve from Zero to Infinity(AUC0-inf)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Maximum Observed Plasma Concentration(Cmax)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Plasma Concentration at 24 Hours Post-Dose(C24h)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Time of Occurrence of Maximum Plasma Concentration(tmax)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Lag Time before Observation of Quantifiable Analyte Concentrations in Plasma(tlag)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Half-Life(t1/2)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Last measurable Non-Zero Concentration(Clast)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Last measurable Non-Zero ConcentrationTime to Last Detectable Concentration(tlast)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Apparent Oral Clearance(CL/F)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Cumulative Urinary Excretion(Ae)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartA: Clearance(CLR)
To describe the PK (plasma and urine) of AZD5004 following a single administration in healthy participants in SAD
Time frame: From Day 1 to Day 6
PartB: Area under the Plasma Concentration vs. Time Curve(AUC0-24)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 1
PartB: Maximum Observed Plasma Concentration(Cmax)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 1, Day 49, Day 63, Day 77, Day91, Day105
PartB: Plasma Concentration at 24 Hours Post-Dose(C24h)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 1
PartB: Time of Occurrence of Maximum Plasma Concentration(tmax)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 1, Day 49, Day 63, Day 77, Day91, Day105
PartB: Lag Time before Observation of Quantifiable Analyte Concentrations in Plasma(tlag)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 1
PartB: Area under the Plasma Concentration vs. Time Curve over the Dosing Interval(AUC0-τ)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 49, Day 63, Day 77, Day 91, Day 105
PartB: Observed Concentration at the End of the Dosing Interval(Cτ)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 49, Day 63, Day 77, Day 91, Day 105
PartB: Half-Life(t1/2)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 49, Day 63, Day 77, Day 91, Day 105
PartB: Apparent Oral Clearance(CL/F)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 49, Day 63, Day 77, Day 91, Day 105
PartB: Cumulative Urinary Excretion(Ae)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 105
PartB: Clearance(CLR)
To describe the PK (plasma and urine) of AZD5004 following repeated daily administration in participants with T2DM in MAD
Time frame: Day 105
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Mar 2025, 4 months.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 4 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elecoglipron